Sage Therapeutics, Inc.
DelistedCIK 1597553fmd_05FG22X1AQDJSZMTZ7DE8E85RHManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2012 to Jun 30, 2025, 50 periods
| Line item | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | 90 | 7 | 1,114 | 6 | 8 | 86 | 41 |
| Research and development | 69 | 121 | 210 | 282 | 369 | 293 | 283 | 326 | 356 | 226 |
| Selling, general and administrative | – | – | 63 | 201 | 346 | 197 | 183 | 228 | 275 | 216 |
| Total operating expenses | 95 | 160 | 273 | 484 | 715 | 518 | 467 | 555 | 666 | 474 |
| Operating income | (95) | (160) | (273) | (393) | (708) | 596 | (461) | (547) | (580) | (432) |
| Other non-operating income (expense) | (0) | (0) | (0) | 0 | 0 | 0 | 0 | 0 | (0) | 0 |
| Income before taxes | – | – | – | (373) | (680) | 606 | (458) | (533) | (541) | (401) |
| Income tax expense | 0 | 0 | 0 | – | – | – | – | – | – | – |
| Net income | (94) | (159) | (270) | (373) | (680) | 606 | (458) | (533) | (541) | (401) |
| Net income to common shareholders | (94) | (159) | – | – | – | – | – | – | – | – |